GT Biopharma Inc (GTBP)

$0.47 +0.02 (3.69%)
Market Cap 4.79M
Revenue (ttm) 0.00
Net Income (ttm) -13.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 559,800
Avg Vol 1,749,398
Day's Range N/A - N/A
Shares Out 10.64M
Stochastic %K 27%
Beta 1.21
Analysts Sell
Price Target $8.00

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advan...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 919 4040
Address:
315 Montgomery Street, 10th Floor, San Francisco, United States
Kaynoshi
Kaynoshi Feb. 25 at 11:17 AM
$GTBP # the sniper
0 · Reply
Wealthboxer
Wealthboxer Feb. 23 at 9:29 PM
$GTBP
0 · Reply
Wealthboxer
Wealthboxer Feb. 23 at 9:27 PM
$GTBP https://x.com/gtbiopharmainc/status/2024849477081735676?s=46
0 · Reply
ClintonMccutcheon458
ClintonMccutcheon458 Feb. 21 at 7:06 AM
$GTBP GT Biopharma develops immuno-oncology therapies. Clinical milestones drive valuation. Early-stage risk remains high.
0 · Reply
Dr_Monkeybreath
Dr_Monkeybreath Feb. 20 at 6:15 PM
$RIME still time at $GTBP 👇
0 · Reply
AztecPyramid
AztecPyramid Feb. 18 at 8:58 AM
$GTBP wow this stock is a piece of caca
0 · Reply
Dr_Monkeybreath
Dr_Monkeybreath Feb. 17 at 1:46 PM
$RIME why not get in early on the next runner with $GTBP ??? 💰💰💰
0 · Reply
Wealthboxer
Wealthboxer Feb. 13 at 6:06 PM
$GTBP $RIME $SRXH
0 · Reply
Investing4Knowledge
Investing4Knowledge Feb. 13 at 9:13 AM
Here’s the penny stock trifecta of dreams 👇 : 1. $RIME 2. $SRXH 3. $GTBP Buy, hold, print 💰
0 · Reply
PymPatterns
PymPatterns Feb. 9 at 3:58 PM
$GTBP GT Biopharma or oncology; pipeline is early-stage and high-risk.
1 · Reply
Latest News on GTBP
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

Feb 17, 2026, 7:30 AM EST - 8 days ago

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

Feb 3, 2026, 8:30 AM EST - 21 days ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

Jan 15, 2026, 8:30 AM EST - 5 weeks ago

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment

Jan 15, 2026, 8:01 AM EST - 5 weeks ago

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Dec 19, 2025, 7:44 AM EST - 2 months ago

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

Nov 19, 2025, 8:00 AM EST - 3 months ago

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 14, 2025, 9:00 AM EST - 3 months ago

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GT Biopharma Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:05 PM EDT - 6 months ago

GT Biopharma Reports Second Quarter 2025 Financial Results

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

Aug 11, 2025, 7:00 AM EDT - 7 months ago

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

GT Biopharma Appoints New Member to its Board of Directors

Jun 13, 2025, 9:00 AM EDT - 9 months ago

GT Biopharma Appoints New Member to its Board of Directors

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

May 19, 2025, 9:00 AM EDT - 10 months ago

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

GT Biopharma Announces Exercise of Warrants

Feb 25, 2025, 2:00 PM EST - 1 year ago

GT Biopharma Announces Exercise of Warrants

GT Biopharma Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:00 PM EST - 1 year ago

GT Biopharma Reports Third Quarter 2024 Financial Results

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 26, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

Sep 24, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

Jun 27, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 21, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

What made GT Biopharma stock more than double on Monday?

May 20, 2024, 10:43 AM EDT - 1 year ago

What made GT Biopharma stock more than double on Monday?

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 15, 2024, 5:00 PM EDT - 1 year ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 26, 2024, 5:00 PM EDT - 2 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Feb 1, 2024, 11:00 AM EST - 2 years ago

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

Dec 6, 2023, 9:30 AM EST - 2 years ago

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Dec 4, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nov 6, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

GT Biopharma Reports Third Quarter 2023 Financial Results

Nov 1, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Third Quarter 2023 Financial Results

GT Biopharma Reports Second Quarter 2023 Financial Results

Aug 7, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Second Quarter 2023 Financial Results

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

Aug 3, 2023, 1:25 PM EDT - 2 years ago

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 15, 2023, 5:00 PM EDT - 3 years ago

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

GT Biopharma Names Charles J. Casamento to the Board of Directors

May 4, 2023, 9:05 AM EDT - 3 years ago

GT Biopharma Names Charles J. Casamento to the Board of Directors

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Mar 30, 2023, 5:00 PM EDT - 3 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Feb 24, 2023, 9:00 AM EST - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Feb 2, 2023, 9:46 AM EST - 3 years ago

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

Dec 30, 2022, 8:00 AM EST - 3 years ago

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Dec 14, 2022, 7:30 AM EST - 3 years ago

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Dec 12, 2022, 7:30 AM EST - 3 years ago

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 10, 2022, 3:15 PM EST - 3 years ago

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

Nov 3, 2022, 9:00 AM EDT - 3 years ago

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Oct 31, 2022, 5:15 PM EDT - 3 years ago

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

Oct 25, 2022, 2:44 PM EDT - 3 years ago

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Oct 6, 2022, 8:18 AM EDT - 3 years ago

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GT Biopharma Announces Adjournment of Special Shareholders Meeting

Oct 4, 2022, 4:10 PM EDT - 3 years ago

GT Biopharma Announces Adjournment of Special Shareholders Meeting

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

Sep 12, 2022, 9:34 AM EDT - 3 years ago

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

Sep 8, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Aug 30, 2022, 6:00 PM EDT - 3 years ago

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Aug 11, 2022, 9:35 AM EDT - 3 years ago

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

Jun 10, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

May 16, 2022, 8:01 AM EDT - 4 years ago

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

May 12, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

Apr 11, 2022, 7:30 AM EDT - 4 years ago

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Mar 28, 2022, 4:15 PM EDT - 4 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Kaynoshi
Kaynoshi Feb. 25 at 11:17 AM
$GTBP # the sniper
0 · Reply
Wealthboxer
Wealthboxer Feb. 23 at 9:29 PM
$GTBP
0 · Reply
Wealthboxer
Wealthboxer Feb. 23 at 9:27 PM
$GTBP https://x.com/gtbiopharmainc/status/2024849477081735676?s=46
0 · Reply
ClintonMccutcheon458
ClintonMccutcheon458 Feb. 21 at 7:06 AM
$GTBP GT Biopharma develops immuno-oncology therapies. Clinical milestones drive valuation. Early-stage risk remains high.
0 · Reply
Dr_Monkeybreath
Dr_Monkeybreath Feb. 20 at 6:15 PM
$RIME still time at $GTBP 👇
0 · Reply
AztecPyramid
AztecPyramid Feb. 18 at 8:58 AM
$GTBP wow this stock is a piece of caca
0 · Reply
Dr_Monkeybreath
Dr_Monkeybreath Feb. 17 at 1:46 PM
$RIME why not get in early on the next runner with $GTBP ??? 💰💰💰
0 · Reply
Wealthboxer
Wealthboxer Feb. 13 at 6:06 PM
$GTBP $RIME $SRXH
0 · Reply
Investing4Knowledge
Investing4Knowledge Feb. 13 at 9:13 AM
Here’s the penny stock trifecta of dreams 👇 : 1. $RIME 2. $SRXH 3. $GTBP Buy, hold, print 💰
0 · Reply
PymPatterns
PymPatterns Feb. 9 at 3:58 PM
$GTBP GT Biopharma or oncology; pipeline is early-stage and high-risk.
1 · Reply
ABN_Newswire
ABN_Newswire Feb. 9 at 12:04 PM
Ellis Martin Report: GT Biopharma, Inc. (NASDAQ:GTBP) Advances Platform Immuno-Oncology Strategy with FDA-Cleared Solid Tumor IND; An Interview with CEO Michael Breen $GTBP http://dlvr.it/TQrlWh
0 · Reply
Wealthboxer
Wealthboxer Feb. 7 at 11:05 PM
$GTBP what’s everyone thinking? Bullish, bearish, or just waiting for a breakout? 🚀📉 #GTBP #AI #NVDA #TSLA #AMD #ARKK #SPY Thoughts on levels to watch or catalysts coming up? 👀💬
0 · Reply
Dr_Monkeybreath
Dr_Monkeybreath Feb. 6 at 7:34 PM
$GTBP anybody who got stopped out or bailed needs to delete this from their watchlist. 🫣
1 · Reply
Bedlam03
Bedlam03 Feb. 6 at 7:08 PM
$GTBP 👀
0 · Reply
harrijakey
harrijakey Feb. 5 at 11:42 AM
$GTBP
0 · Reply
kate8delgado8
kate8delgado8 Feb. 5 at 11:37 AM
$GTBP
0 · Reply
Trader5678
Trader5678 Feb. 4 at 8:31 PM
$GTBP I'm in! Let's see if this Phase 1 thingy sparks any interest
0 · Reply
Dr_Monkeybreath
Dr_Monkeybreath Feb. 4 at 7:16 PM
$GTBP filled another 1,000 @ .485. keep it cheap til payday and i will add more.👍
0 · Reply
stocks_2watch
stocks_2watch Feb. 4 at 5:10 PM
$GTBP, GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®️: https://www.gtbiopharma.com/news-media/press-releases/detail/304/gt-biopharma-announces-fda-clearance-of-investigational-new
0 · Reply
Tonyboner
Tonyboner Feb. 4 at 3:14 PM
$GTBP Tried to warn you, could go lower than 30c if they let it bleed without a raise.
1 · Reply
Kaynoshi
Kaynoshi Feb. 4 at 11:02 AM
$GTBP FAAAAAHHHHH
0 · Reply
StockGuru95
StockGuru95 Feb. 4 at 10:22 AM
$GTBP FDA cleared human testing of its experimental drug GTB‑5550 for advanced cancers. Time to rise ⬆️
0 · Reply